Long Term Visual And Refractive Outcomes Of Eyecryl® Phakic Intraocular Lens Implantation For Management Of High Myopia And Myopic Astigmatism

To evaluate the long term outcomes of Eyecryl phakic intraocular lens (pIOL) implantation for high myopia and myopic astigmatism. 

Nethradhama Superspeciality Eye Hospital, Bengaluru, Karnataka, India

Electronic Medical records of patients who had implantation of Eyecryl pIOL or Eyecryl phakic Toric IOL from Aug 2017 to July 2022 were retrospectively reviewed. Patients with a follow-up period of a minimum of 12 months were included in the study. Visual and refractive results, endothelial cell density, central vault, and complications were evaluated.

A total of 186 eyes from 106 patients (mean age=30.07 years) were analysed.Thirty three spherical and 153 toric phakic IOLs were implanted. Mean follow up was 37.04±13.60 months (3.08 years). The preoperative sphere, cylinder, SE reduced significantly from -9.91 ±5.22 D, -1.67±1.15 D and -10.75 ± 5.35 D to -0.03± 0.29D, -0.09± 0.32D, -0.07 ± 0.35D respectively (p- value >0.05). The mean efficacy and safety indices were 1.02 and 1.01 respectively. The mean central vault was 497.86±167.75µ at 2 weeks, which reduced to 481.49±162.07 µ at 3.08 years,( p- <0.001). Endothelial cell( EC) loss was 2.4 % in the first 12 months.Two eyes of toric pIOL required realignment. No eye developed cataract, glaucoma, retinal detachment or severe inflammation.

At the end of 37.04±13.60 months (3.09 years) follow-up, Eyecryl pIOL implantation was found to be safe and effective surgical procedure for correction of high myopia and myopic astigmatism.